Edward Hallen, an officer and director of Klaviyo, Inc., filed a Form 144 notice on November 5, 2026, proposing to sell 98,782 shares of Klaviyo Series A stock on the NYSE with an aggregate market value of $2,005,274.60.
Key Highlights
- Proposed sale: 98,782 Series A shares with an aggregate market value of $2,005,274.60, to be executed through Fidelity Brokerage Services LLC.
- Approximate sale date: November 5, 2026, on the NYSE.
- Original acquisition: Shares were acquired on September 25, 2012 as Founders Shares from the issuer, with payment classified as compensation.
- Shares outstanding: 130,150,680 Series A shares outstanding at the time of the notice, according to the filing.
- Rule 10b5-1 plan: The filing indicates a trading plan or instruction date of June 1, 2026.
- Prior three-month sales: Affiliated entities Hodgkins Trust and Hodgkins LLC sold a combined 197,564 Series A shares between August 31, 2026 and October 7, 2026, generating gross proceeds totaling $3,741,161.90.
- Relationship to issuer: Edward Hallen is listed as both an officer and a director of Klaviyo, Inc.
Hallen's Proposed Sale: Founders Shares Through Affiliated Entities
According to the Form 144 filing, Edward Hallen, identified as an officer and director of Klaviyo, Inc. (NYSE:KVYO), proposes to sell 98,782 Series A shares with an aggregate market value of $2,005,274.60. The filing states that the shares were originally acquired on September 25, 2012, as Founders Shares from the issuer, with the nature of payment listed as compensation. The broker named for the transaction is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.
The filing's remarks section discloses that "today's sale includes 59,615 shares sold from Hodgkins LLC, of which Edward W Hallen is an authorized individual and account stakeholder; and 39,167 shares sold from Hodgkins Trust, of which Edward W. Hallen is an account stakeholder." The combined total of these two components equals the 98,782 shares proposed for sale. The filing also notes the adoption of a Rule 10b5-1 trading plan or instruction dated June 1, 2026.
In the three months prior to this notice, the filing reports that Hodgkins Trust and Hodgkins LLC conducted a series of Series A share sales. Hodgkins Trust sold 39,167 shares on August 31, 2026 for $801,622.32; Hodgkins LLC sold 59,615 shares on the same date for $1,221,349.02. Additional sales occurred on September 24, 2026 (500 shares from Hodgkins Trust for $8,509.50; 800 shares from Hodgkins LLC for $13,614.50) and October 7, 2026 (38,667 shares from Hodgkins Trust for $672,750.93; 58,815 shares from Hodgkins LLC for $1,023,315.63).
What Was Disclosed
Klaviyo officer and director Edward Hallen filed a Form 144 notice proposing to sell 98,782 Series A shares on November 5, 2026, through affiliated entities Hodgkins Trust and Hodgkins LLC, under a Rule 10b5-1 plan adopted June 1, 2026.



Please wait processing your request...